Bortezomib-induced tumor lysis syndrome in multiple myeloma

Orhan Sezer*, David H. Vesole, Seema Singhal, Paul Richardson, Edward Stadtmauer, Christian Jakob, Anthony L. Boral, Dixie Lee Esseltine, Jayesh Mehta

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Tumor lysis syndrome (TLS) is exceedingly rare in multiple myeloma because of the relatively slow proliferation and response of the malignant cells. Bortezomib is a novel agent that inhibits proteasome and has shown activity against multiple myeloma. We report 8 episodes of TLS seen in 7 patients with bortezomib therapy, with or without dexamethasone, among 496 patients treated on 3 phase II multicenter studies. Biochemical abnormalities resolved with supportive therapy in 6 patients (including hemodialysis in 2) but proved fatal in 1. Clinicians should be alert for TLS in patients with myeloma with significant disease burden treated with bortezomib because of the potential for rapid onset of cell lysis with this agent.

Original languageEnglish (US)
Pages (from-to)233-235
Number of pages3
JournalClinical Lymphoma and Myeloma
Issue number3
StatePublished - Nov 2006


  • Dexamethasone
  • Hemodialysis
  • Proteasome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Bortezomib-induced tumor lysis syndrome in multiple myeloma'. Together they form a unique fingerprint.

Cite this